Overview
NTRA market data
Price History
NTRA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.52 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $131.81 – $288.04 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $37.9K · P/B 18.50 · P/S 15.14.
Company news
Natera Publishes Results From Prospective, Multicenter Study In Merkel Cell Carcinoma In The JAMA Dermatology Journal; Signatera Test Was A Significantly Stronger Predictor Of Recurrence Than AMERKBenzinga · Jul 22, 2026, 10:05 AM
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer MonitoringBenzinga · Jul 21, 2026, 6:52 PM
Reported Earlier, Natera Highlights Finalized MolDx LCD Expanding Prospera Testing Coverage Across Kidney, Heart, And Lung Transplant Surveillance SettingsBenzinga · Jul 17, 2026, 6:02 AM
Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $330Benzinga · Jul 14, 2026, 11:57 AM
Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $310Benzinga · Jul 9, 2026, 5:30 PM
Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $300Benzinga · Jul 6, 2026, 4:35 PM
Guggenheim Maintains Buy on Natera, Raises Price Target to $290Benzinga · Jun 29, 2026, 2:10 PM
CORRECTION: Bernstein Reinstates Outperform on Natera, Announces $310 Price TargetBenzinga · Jun 26, 2026, 2:00 PM
Bernstein Reiterates Outperform on Natera, Announces $310 Price TargetBenzinga · Jun 26, 2026, 1:25 PM
Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney TransplantationBenzinga · Jun 25, 2026, 11:15 AM